Skip to main content

CRISPR Therapeutics AG

corporate_fare Company Profile

CRISPR Therapeutics AG

CRSP·NASDAQ·Life Sciences·CIK 0001674416

CRISPR Therapeutics AG is a biopharmaceutical company focused on developing gene-based medicines using CRISPR/Cas9 technology. This technology allows for the precise alteration of specific genomic DNA sequences. The company achieved the first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023, in collaboration with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG's therapeutic programs are organized into four core franchises: hemoglobinopathies, in vivo approaches, CAR T approaches, and regenerative medicine. The company employs either an ex vivo approach, editing cells outside the body before administration, or an in vivo editing approach, delivering the therapeutic directly to target cells within the body. In the hemoglobinopathies franchise, CASGEVY has received approval in the United States and other countries for treating eligible patients with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). Further research in this area, also with Vertex, includes targeted conditioning and in vivo editing of hematopoietic stem cells. The in vivo approaches franchise is developing a portfolio of programs for common and rare diseases, utilizing both in vivo editing and siRNA approaches. The CAR T franchise is advancing next-generation gene-edited cell therapy programs, including allogeneic chimeric antigen receptor T cell (CAR T) candidates for autoimmune indications and oncology. Lastly, the regenerative medicine franchise is developing a deviceless beta cell replacement product candidate, consisting of unencapsulated precursor islet cells derived from induced pluripotent stem cells, for the treatment of Type 1 diabetes (T1D).

CRISPR Therapeutics AG (NASDAQ:CRSP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for CRSP at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • CRISPR Therapeutics Reports Widened Annual Loss, Increased CASGEVY Program Costs, and New Patent Litigation
  • CRISPR Therapeutics Reports Q4 & FY25 Results, Highlights Strong CASGEVY Uptake & Pipeline Progress
  • CRISPR Therapeutics Reports Positive Clinical Data for CTX310 and Autoimmune CAR-T Zugo-cel, Advances Pipeline

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.51M
Net Income
-$581.6M
Diluted EPS
-$6.47
Op. Cash Flow
-$345.01M
Free Cash Flow
-$345.93M
Operating Income
-$664.57M
Cash & Equivalents
$347.56M
Debt / Equity
0.00×
Net Margin
-165.70×
Shares Outstanding
95.89M sh
Source: 10-K · filed 2026-02-12 · accession 0001193125-26-048957
$39.5 +1.02% today
52-week range · as of 2026-11-02 $39.5 – $65.98
Market cap
$3.79B
Volume
3.3M (1.7× avg)
3-mo avg 1.9M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRSP - Filings & News (Page 2)

CRSP
Feb 12, 2026, 4:59 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $49.95
Real-time Price: $39.50 info
Change: -$10.45 (-21%) info
Market Cap: $3.793B info
CRSP
Feb 12, 2026, 4:35 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $49.79
Real-time Price: $39.50 info
Change: -$10.29 (-21%) info
Market Cap: $3.793B info
CRSP
Jan 12, 2026, 8:44 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.30
Real-time Price: $39.50 info
Change: -$14.80 (-27%) info
Market Cap: $3.793B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets